{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:25:07Z","timestamp":1787019907891,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Giant cell arteritis (GCA) remains a medical emergency because of the risk of sudden irreversible sight loss and rarely stroke along with other complications. Because headache is one of the cardinal symptoms of cranial GCA, neurologists need to be up to date with the advances in investigation and management of this condition. The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based recommendations on GCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The working group identified relevant questions, performed systematic literature review and assessed the quality of available evidence, and wrote recommendations. Where there was not a high level of evidence, the multidisciplinary (neurology, ophthalmology and rheumatology) group recommended best practice based on their clinical experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across Europe, fast track pathways and the utility of advanced imaging techniques are helping to reduce diagnostic delay and uncertainty, with improved clinical outcomes for patients. GCA is treated with high dose glucocorticoids (GC) as a first line agent however long-term GC toxicity is one of the key concerns for clinicians and patients. The first phase 2 and phase 3 randomised controlled trials of Tocilizumab, an IL-6 receptor antagonist, have been published. It is now been approved as the first ever licensed drug to be used in GCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present article will outline recent advances made in the diagnosis and management of GCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-020-01093-7","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T12:33:21Z","timestamp":1584448401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["European Headache Federation recommendations for neurologists managing giant cell arteritis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"S. P.","family":"Mollan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Paemeleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Luqmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-5132","authenticated-orcid":false,"given":"A. J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"issue":"10","key":"1093_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","volume":"13","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B (2017) Giant cell arteritis and polymyalgia: current challenges and opportunities. Nat Rev Rheumatol 13(10):578\u2013592","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1093_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"6\u20137","key":"1093_CR3","doi-asserted-by":"publisher","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","volume":"11","author":"AT Borchers","year":"2012","unstructured":"Borchers AT, Gershwin ME (2012) Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 11(6\u20137):A544\u2013A554","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1093_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40123-019-0171-0","volume":"8","author":"AZ Al-Mousawi","year":"2019","unstructured":"Al-Mousawi AZ, Gurney SP, Lorenzi AR, Pohl U, Dayan M, Mollan SP (2019) Reviewing the pathophysiology behind the advances in the Management of Giant Cell Arteritis. Ophthalmol Ther 8(2):177\u2013193","journal-title":"Ophthalmol Ther"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"43953","DOI":"10.1038\/srep46012","volume":"7","author":"FD Carmona","year":"2017","unstructured":"Carmona FD, Coit P, Saruhan-Direskeneli G, Hern\u00e1ndez-Rodr\u00edguez J, Cid MC, Solans R et al (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953. https:\/\/doi.org\/10.1038\/srep46012","journal-title":"Sci Rep"},{"issue":"1","key":"1093_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13075-015-0692-4","volume":"17","author":"SL Mackie","year":"2015","unstructured":"Mackie SL, Taylor JC, Haroon-Rashid L et al (2015) Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Res Ther 17(1):195","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1093_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/03009742.2014.982701","volume":"44","author":"AK Chandran","year":"2015","unstructured":"Chandran AK, Udayakumar PD, Crowson C et al (2015) The incidence of Giant cell arteritis in Olmsted County Minnesota, over a sixty year period 1950 \u2013 2009. Scand J Rheumatol 44(3):215\u2013218","journal-title":"Scand J Rheumatol"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E et al (2011) The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63:633\u2013639","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1093_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-017-1479-6","volume":"19","author":"LK Brekke","year":"2017","unstructured":"Brekke LK, Brekke LK, Diamantopoulos AP, Fevang BT, A\u03b2mus J, Esper\u00f8 E, Gjesdal CG (2017) Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Arthritis Res Ther 19(1):278 [published correction appears in Arthritis Res Ther. 2018 Dec 7;20(1):271]","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1093_CR10","first-page":"524","volume":"56","author":"M Yates","year":"2017","unstructured":"Yates M, Macgregor AJ, Robson J, Craven A, Merkel PA, Luqmani RA, Watts RA (2017) The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology (Oxford) 56(4):524\u2013528","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 117(2)","key":"1093_CR11","first-page":"61","volume":"37","author":"M Czihal","year":"2019","unstructured":"Czihal M, Tschaidse J, Bernau C, Lottspeich C, K\u00f6hler A, Dechant C, Schulze-Koops H, Hoffmann U, Mackert MJ, Thurau S (2019) Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment. Clin Exp Rheumatol 37(Suppl 117(2)):61\u201364","journal-title":"Clin Exp Rheumatol"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-2008-1041094","volume":"14","author":"RJ Caselli","year":"1994","unstructured":"Caselli RJ, Hunder GG (1994) Neurologic complications of giant cell (temporal) arteritis. Semin Neurol 14:349\u2013353","journal-title":"Semin Neurol"},{"issue":"6","key":"1093_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.12998\/wjcc.v3.i6.484","volume":"3","author":"C Ponte","year":"2015","unstructured":"Ponte C, Rodrigues AF, O'Neill L, Luqmani RA (2015) Giant cell arteritis: current treatment and management. World J Clin Cases 3(6):484\u2013494","journal-title":"World J Clin Cases"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","volume":"88","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I et al (2009) Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88:227\u2013235","journal-title":"Medicine (Baltimore)"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12916-017-0871-z","volume":"15","author":"JA Prior","year":"2017","unstructured":"Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T (2017) Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis. BMC Med 15:120","journal-title":"BMC Med"},{"issue":"2","key":"1093_CR16","doi-asserted-by":"publisher","first-page":"e019320","DOI":"10.1136\/bmjopen-2017-019320","volume":"8","author":"T Helliwell","year":"2018","unstructured":"Helliwell T, Muller S, Hider SL, Prior JA, Richardson JC, Mallen CD (2018) Challenges of diagnosis and management of giant cell arteritis in general practice: a multimethods study. BMJ Open 8(2):e019320 Published 2018 Feb 3","journal-title":"BMJ Open"},{"issue":"2","key":"1093_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/keu433","volume":"54","author":"SP Mollan","year":"2015","unstructured":"Mollan SP, Begaj I, Mackie S et al (2015) Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. Rheumatology (Oxford) 54(2):375\u2013377","journal-title":"Rheumatology (Oxford)"},{"issue":"2 Suppl 89","key":"1093_CR18","first-page":"S-103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):S-103\u2013S-106","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1093_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/rheumatology\/kem322","volume":"47","author":"WA Schmidt","year":"2008","unstructured":"Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 47(1):96\u2013101","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1093_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco C, Ramiro S, Duftner C et al (2018 May) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636\u2013643","journal-title":"Ann Rheum Dis"},{"key":"1093_CR21","doi-asserted-by":"publisher","unstructured":"Coath F, Gillbert K, Griffiths B et al (2018) Giant cell arteritis: new concepts, treatments and the unmet need that remains. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/key326","DOI":"10.1093\/rheumatology\/key326"},{"issue":"1","key":"1093_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"5","key":"1093_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.semarthrit.2016.11.002","volume":"46","author":"K Tuckwell","year":"2017","unstructured":"Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E et al (2017) Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum 46(5):657\u2013664","journal-title":"Semin Arthritis Rheum"},{"issue":"13","key":"1093_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003213","volume":"95","author":"F Sun","year":"2016","unstructured":"Sun F, Ma S, Zheng W, Tian X, Zeng X (2016) A retrospective study of Chinese patients with Giant cell arteritis (GCA): clinical features and factors associated with severe ischemic manifestations. Medicine (Baltimore) 95(13):e3213","journal-title":"Medicine (Baltimore)"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/OPTH.S193460","volume":"13","author":"EB Ing","year":"2019","unstructured":"Ing EB, Miller NR, Nguyen A et al (2019) Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation. Clin Ophthalmol 13:421\u2013430","journal-title":"Clin Ophthalmol"},{"issue":"16","key":"1093_CR26","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2169\/internalmedicine.50.5205","volume":"50","author":"N Imai","year":"2011","unstructured":"Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M (2011) Giant cell arteritis: clinical features of patients visiting a headache Clinic in Japan. Intern Med 50(16):1679\u20131682","journal-title":"Intern Med"},{"issue":"6072","key":"1093_CR27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/bmj.1.6072.1355-b","volume":"1","author":"RV Jones","year":"1977","unstructured":"Jones RV (1977) Unbearable headache of temporal arteritis. Br Med J 1(6072):1355","journal-title":"Br Med J"},{"issue":"5","key":"1093_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5114\/reum.2016.63663","volume":"54","author":"C Manzo","year":"2016","unstructured":"Manzo C (2016) Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica. Reumatologia 54(5):236\u2013238","journal-title":"Reumatologia"},{"issue":"7","key":"1093_CR29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D et al (2015) Disease relapses among patients with Giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 42(7):1213\u20131217","journal-title":"J Rheumatol"},{"issue":"7","key":"1093_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/rheumatology\/kex075","volume":"56","author":"B Seeliger","year":"2017","unstructured":"Seeliger B, Sznajd J, Robson JC et al (2017) Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford) 56(7):1154\u20131161","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1093_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL et al (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54(3):463\u2013470","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1093_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","volume":"41","author":"TA Kermani","year":"2011","unstructured":"Kermani TA, Schmidt J, Crowson CS et al (2011) Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 41(6):866\u2013871","journal-title":"Semin Arthritis Rheum"},{"key":"1093_CR33","doi-asserted-by":"crossref","unstructured":"Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. (2002) Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 109(7):1267\u201371.","DOI":"10.1016\/S0161-6420(02)01076-X"},{"issue":"10","key":"1093_CR34","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.ophtha.2006.05.020","volume":"113","author":"M Parikh","year":"2006","unstructured":"Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W et al (2006) Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 113(10):1842\u20131845","journal-title":"Ophthalmology"},{"issue":"4","key":"1093_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1600-0420.2006.00864.x","volume":"85","author":"P Yu-Wai-Man","year":"2007","unstructured":"Yu-Wai-Man P, Dayan MR (2007) Acta Ophthalmol Scand 85(4):460","journal-title":"Acta Ophthalmol Scand"},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.eye.6700240","volume":"17","author":"TR Poole","year":"2003","unstructured":"Poole TR, Graham EM, Lucas SB (2003) Giant cell arteritis with a normal ESR and CRP. Eye 17:92\u201393","journal-title":"Eye"},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","volume":"84","author":"MA Gonzalez-Gay","year":"2005","unstructured":"Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ et al (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84:269\u2013276","journal-title":"Medicine (Baltimore)"},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani C, Della BC, Cimino L et al (2009) Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48:250\u2013253","journal-title":"Rheumatology (Oxford)"},{"key":"1093_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid MC, Font C, Oristrell J et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41:26\u201332","journal-title":"Arthritis Rheum"},{"key":"1093_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O\u2019Fallon WM, Hunder GG (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703\u2013708","journal-title":"Arthritis Rheum"},{"key":"1093_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S127812","volume":"10","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Horsburgh J, Dasgupta B (2018) Profile of tocilizumab and its potential in the treatment of giant cell arteritis. Eye Brain 10:1\u201311","journal-title":"Eye Brain"},{"issue":"8","key":"1093_CR42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/0333102411409073","volume":"31","author":"M Cambron","year":"2011","unstructured":"Cambron M (2011) De Raedt, Versijpt J, Geers C, Brouns R. a halo may lead the way. Cephalalgia 31(8):971\u2013972","journal-title":"Cephalalgia"},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.autrev.2018.07.012","volume":"18","author":"M Rinagel","year":"2019","unstructured":"Rinagel M, Chatelus E, Jousse-Joulin S et al (2019) Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: asystematic review and meta-analysis of the literature. Autoimmun Rev 18:56\u201361","journal-title":"Autoimmun Rev"},{"key":"1093_CR44","first-page":"S-113","volume":"33","author":"M Aschwanden","year":"2015","unstructured":"Aschwanden M, Imfeld S, Staub D, Baldi T, Walker UA, Berger CT et al (2015) The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol 33:S-113\u2013S-115","journal-title":"Clin Exp Rheumatol"},{"issue":"90","key":"1093_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20900","volume":"20","author":"R Luqmani","year":"2016","unstructured":"Luqmani R, Lee E, Singh S et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of Giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20(90):1\u2013238","journal-title":"Health Technol Assess"},{"issue":"2","key":"1093_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/rheumatology\/kex173","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Floris A, Ponte C et al (2018) The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology (Oxford) 57(2):227\u2013235","journal-title":"Rheumatology (Oxford)"},{"key":"1093_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/rheumatology\/kex341","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Floris A, Ponte C et al (2018) The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology 57:112\u2013119","journal-title":"Rheumatology"},{"key":"1093_CR48","doi-asserted-by":"publisher","unstructured":"Sammel AM, Hsiao E, Schembri G et al (2019) Diagnostic accuracy of PET\/CT scan of the head, neck and chest for Giant cell arteritis: the double-blinded Giant cell arteritis and PET scan (GAPS) study. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.40864","DOI":"10.1002\/art.40864"},{"issue":"12","key":"1093_CR49","doi-asserted-by":"publisher","first-page":"987","DOI":"10.7326\/0003-4819-120-12-199406150-00003","volume":"120","author":"AA Achkar","year":"1994","unstructured":"Achkar AA, Lie JT, Hunder GG, O\u2019Fallon WM, Gabriel SE (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120(12):987\u2013992","journal-title":"Ann Intern Med"},{"issue":"9","key":"1093_CR50","first-page":"1252","volume":"116","author":"RA Guevara","year":"1998","unstructured":"Guevara RA, Newman NJ, Grossniklaus HE (1998) Positive temporal artery biopsy 6 months after prednisone treatment. Arch Ophthalmol 116(9):1252\u20131253","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1093_CR51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4997\/JRCPE.2015.403","volume":"45","author":"A Croft","year":"2015","unstructured":"Croft A, Thompson N, Duddy M et al (2015) Cranial ultrasound for the diagnosis of giant cell arteritis. A retrospective cohort study. J R Coll Physicians Edinb 45(4):268\u2013272","journal-title":"J R Coll Physicians Edinb"},{"issue":"7","key":"1093_CR52","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","volume":"45","author":"RHJA Slart","year":"2018","unstructured":"Slart RHJA (2018) Writing group; reviewer group; FDG-PET\/CT(a) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET interest group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 45(7):1250\u20131269","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6 Suppl 32","key":"1093_CR53","first-page":"S15","volume":"21","author":"D Blockmans","year":"2003","unstructured":"Blockmans D (2003) The use of (18F) fluorodeoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol 21(6 Suppl 32):S15\u2013S22","journal-title":"Clin Exp Rheumatol"},{"issue":"37","key":"1093_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001542","volume":"94","author":"MD Stellingwerff","year":"2015","unstructured":"Stellingwerff MD, Brouwer E, Lensen KJ, Rutgers A, Arends S, van der Geest KS et al (2015) Different scoring methods of FDG PET\/CT in Giant cell arteritis: need for standardization. Medicine (Baltimore) 94(37):e1542","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1093_CR55","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1148\/radiol.14140056","volume":"273","author":"T Klink","year":"2014","unstructured":"Klink T, Geiger J, Both M et al (2014) Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 273(3):844\u2013852","journal-title":"Radiology"},{"key":"1093_CR56","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1109\/TUFFC.2018.2868674","volume":"66","author":"R Sheikh","year":"2019","unstructured":"Sheikh R, Cinthio M, Dahlstrand U, Erlov T, Naumovska M, Hammar B, Zackrisson S, Jansson T, Reistad N, Malmsjo M (2019) Clinical translation of a novel photoacoustic imaging system for examining the temporal artery. IEEE Trans Ultrason Ferroelectr Freq Control 66:472\u2013480","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"issue":"1","key":"1093_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/eye.2016.206","volume":"31","author":"S Mollan","year":"2017","unstructured":"Mollan S, Keane P, Denniston A (2017) The use of transdermal optical coherence tomography to image the superficial temporal arteries. Eye 31(1):157\u2013160","journal-title":"Eye"},{"issue":"1","key":"1093_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55(1):66\u201370","journal-title":"Rheumatology (Oxford)"},{"key":"1093_CR59","doi-asserted-by":"crossref","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u201330.","DOI":"10.1136\/annrheumdis-2019-215672"},{"issue":"10","key":"1093_CR60","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54(10):3310\u20133318","journal-title":"Arthritis Rheum"},{"key":"1093_CR61","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, De Wazieres B, Dien G, Duhamel E, Grosbois B, Jego P, La Strat A, Capedeville J, Letellier P, Agron L (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis:a one year followup study of 164 patients. J Rheumatol 27:1484\u20131491","journal-title":"J Rheumatol"},{"key":"1093_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000070631","volume":"217","author":"SS Hayreh","year":"2003","unstructured":"Hayreh SS, Zimmerman B (2003) Management of giant cell arteritis: our 27-year clinical study; new light on old controversies. Ophthalmologica 217:239\u2013259","journal-title":"Ophthalmologica"},{"key":"1093_CR63","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"HV Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer HV, Savino PJ, Gamble GG (2005) Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112:1098\u20131103","journal-title":"Ophthalmology"},{"issue":"4","key":"1093_CR64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of tocilizumab in Giant-cell arteritis. N Engl J Med 377(4):317\u2013328","journal-title":"N Engl J Med"},{"key":"1093_CR65","unstructured":"NICE Clinical knowledge summaries. Scenario: Corticosteroids: covers the management of people receiving oral corticosteroids in primary care. https:\/\/cks.nice.org.uk\/corticosteroids-oral#!scenario. Last accessed 9 July 2019"},{"key":"1093_CR66","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","volume":"67","author":"H Petri","year":"2015","unstructured":"Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res 67:390\u2013395","journal-title":"Arthritis Care Res"},{"key":"1093_CR67","doi-asserted-by":"crossref","unstructured":"Dumont A, Parienti JJ, Delmas C, Boutemy J, Maign\u00e9 G, Silva NM et al. (2020) Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis. J Rheumatol 47(1):108\u2013116.","DOI":"10.3899\/jrheum.181127"},{"issue":"5","key":"1093_CR68","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MD.0000000000000033","volume":"93","author":"MA Alba","year":"2014","unstructured":"Alba MA, Garcia-Martinez A, Prieto-Gonzalez S et al (2014) Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 93(5):194\u2013201","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1093_CR69","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","volume":"46","author":"MS Broder","year":"2016","unstructured":"Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46(2):246\u2013252","journal-title":"Semin Arthritis Rheum"},{"key":"1093_CR70","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106\u2013114","journal-title":"Ann Intern Med"},{"key":"1093_CR71","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309\u20131318","journal-title":"Arthritis Rheum"},{"key":"1093_CR72","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG et al (2001) A prospective, double-blind, randomized, placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495\u2013501","journal-title":"Clin Exp Rheumatol"},{"key":"1093_CR73","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD (2007) Over JA, Spiera RF, Hern\u00e1ndez-Garc\u00eda C, Fern\u00e1ndez-Guti\u00e9rrez B, Lavalley MP, Merkel PA. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789\u20132797","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1093_CR74","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M De Silva","year":"1986","unstructured":"De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45(2):136\u2013138","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1093_CR75","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/rheumatology\/kes127","volume":"51","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E et al (2012) Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 51(9):1677\u20131686","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1093_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF03325257","volume":"24","author":"S Sciascia","year":"2012","unstructured":"Sciascia S, Piras D, Baldovino S, Russo A, Naretto C, Rossi D et al (2012) Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res 24(3):273\u2013277","journal-title":"Aging Clin Exp Res"},{"key":"1093_CR77","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/rheumatology\/37.4.464","volume":"37","author":"C Schaufelberger","year":"1998","unstructured":"Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Rheumatology 37:464\u2013465","journal-title":"Rheumatology"},{"key":"1093_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204462","volume":"73","author":"M Samson","year":"2014","unstructured":"Samson M, Audia S, Janikashvili N, Bonnotte B (2014) Is TNF-alpha really involved in giant cell arteritis pathogenesis? Ann Rheum Dis 73:e1","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1093_CR79","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","volume":"38","author":"A Ho\u010devar","year":"2019","unstructured":"Ho\u010devar A, Je\u0161e R, Rotar \u017d, Tom\u0161i\u010d M (2019) Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol 38(2):291\u2013296","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1093_CR80","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50(4):1332\u20131337","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1093_CR81","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee MS, Smith SD, Galor A, Hoffman GS (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54(10):3306\u20133309","journal-title":"Arthritis Rheum"},{"key":"1093_CR82","first-page":"S57","volume":"26","author":"J Narvaez","year":"2008","unstructured":"Narvaez J, Bernad B, Gomez-Vaquero C, Garcia-Gomez C, Roig-Vilaseca D, Juanola X et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26:S57\u2013S62","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1093_CR83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","volume":"48","author":"CT Berger","year":"2009","unstructured":"Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C (2009) High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 48(3):258\u2013261","journal-title":"Rheumatology (Oxford)"},{"key":"1093_CR84","first-page":"Cd010453","volume":"8","author":"SP Mollan","year":"2014","unstructured":"Mollan SP, Sharrack N, Burdon MA, Denniston AK (2014) Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev 8:Cd010453","journal-title":"Cochrane Database Syst Rev"},{"issue":"10031","key":"1093_CR85","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387(10031):1921\u20131927","journal-title":"Lancet"},{"key":"1093_CR86","doi-asserted-by":"crossref","unstructured":"Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, et al. Long-term outcome of tocilizumab for patients with Giant Cell Arteritis: results from part 2 of the GiACTA Tiral. EULAR 13th June 2019: Oral Presentation # OP0140","DOI":"10.1136\/annrheumdis-2019-eular.2099"},{"issue":"3","key":"1093_CR87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4997\/JRCPE.2017.308","volume":"47","author":"P Jobanputra","year":"2017","unstructured":"Jobanputra P, Ford M (2017) Tocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis. J R Coll Physicians Edinb 47(3):250\u2013252","journal-title":"J R Coll Physicians Edinb"},{"issue":"3","key":"1093_CR88","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S et al (2020) British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford) 59(3):e1\u2013e23","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-020-01093-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T19:57:28Z","timestamp":1666123048000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01093-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01093-7","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SPM \u2013 advisory board and speaker fees for Roche; speaker fees for Chugai-roche Ltd.KP - none relating to the manuscript.JV - none relating to the manuscript.RL - advisory board and speaker fees for Roche; speaker fees for AbbVie, Chugai-Roche Ltd.; grants from Celgene, Roche, Vifor.AS - speaker fees for Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}